DBDawn M. Boothe

Dawn M. Boothe

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Dawn M. Boothe has a total of 11 co-authors. Here are the top co-authors by number of shared publications:

  • Alex Jenkins

    Clincal Pharmacology Laboratory, Department of Anatomy, Physiology and Pharmacology College of Veterinary Medicine, Auburn University Auburn Alabama USA

    1 shared publication
  • Amelia G. White

    Department of Clinical Sciences College of Veterinary Medicine, Auburn University Auburn Alabama USA

    1 shared publication
  • Crisanta Cruz-Espindola

    Department of Anatomy, Physiology and Pharmacology, College of Veterinary Medicine Auburn University Auburn Alabama USA

    1 shared publication
  • Crisanta Cruz‐Espindola

    Clincal Pharmacology Laboratory, Department of Anatomy, Physiology and Pharmacology College of Veterinary Medicine, Auburn University Auburn Alabama USA

    1 shared publication
  • Hsuan‐Ping Hong

    Department of Veterinary Medicine and Surgery, College of Veterinary Medicine University of Missouri Columbia Missouri USA

    1 shared publication
  • Joan R. Coates

    Department of Veterinary Medicine and Surgery, College of Veterinary Medicine, University of Missouri, Columbia, MO 65211, USA

    1 shared publication

Latest Publications

  • Comparison of the In Vitro Dissolution Profiles for Cyclosporine Formulations

    by Nicole E. Alleva, Hsuan‐Ping Hong, Joan R. Coates, Nai‐Wei Chen, Crisanta Cruz‐Espindola, Dawn M. Boothe

    Atopica (formerly Novartis, now Elanco Animal Health) is the pioneer veterinary‐approved modified cyclosporine authorized by both the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Despite the availability of several veterinary‐specific generics, human generics are frequently substituted extra‐label in clinical practice. However, therapeutic equivalence in humans does not guarantee equal bioavailability in dogs, whether comparing these products to one another or to Atopica. As a Biopharmaceutics Classification System Class II compound, cyclosporine's oral absorption is primarily determined by its dissolution rate. This study compared the in vivo dissolution profiles of three human cyclosporine products including Neoral (Novartis), TEVA (TEVA Pharmaceuticals), and Apotex (Apotex Inc) with Atopica using a Distek 2100 A system (USP Apparatus 2, 50 rpm, 500 mL deionized water, 37°C). Primary outcomes included visual capsule rupture time and cyclosporine concentration at 7.5, 15, and 30 min, quantified by high‐performance liquid chromatography. Neoral exhibited a shorter mean capsule rupture time compared to Atopica, while TEVA and Apotex showed no difference. At the 30‐min mark, no significant differences in concentrations were observed among the products. While these in vitro results suggest comparable dissolution at a critical absorption 30‐min time point, the shorter capsule rupture time of Neoral highlights formulation‐specific differences. Comprehensive in vivo pharmacokinetic studies are warranted to determine if these human generics are truly interchangeable with Atopica or one another in dogs.

  • Evaluation of Compatibility and Stability of Compounded Otic Solutions Containing Enrofloxacin Over a 20‐Day Period

    by Shae Atterberg, Amelia White, Crisanta Cruz‐Espindola, Kamoltip Thungrat, Alex Jenkins, Zachary Lough, Dawn Boothe

    Background: Compounded otic solutions containing enrofloxacin are commonly used in the management of otitis. Hypothesis/Objectives: The study objective was to evaluate the compatibility and stability of enrofloxacin in compounded otic solutions, as determined by physical changes and quantitated strength. Materials and Methods: Twelve solutions containing 100 mg/mL enrofloxacin (Baytril 100; Elanco) or 22.7 mg/mL enrofloxacin (Baytril; Elanco) were quantitatively analysed on Day (D)0, D10, D15, and D20. Both concentrations of enrofloxacin were combined with sterile water (Hospira), tris‐EDTA (TrizEDTA; Dechra), sterile water and 4 mg/mL dexamethasone sodium phosphate (dexamethasone, Dexium‐SP; Bimeda), tris‐EDTA and dexamethasone, tris‐EDTA with 0.15% ketoconazole (TrizULTRA Keto; Dechra) and dexamethasone, and 1% miconazole nitrate lotion (Covetrus) and dexamethasone. Gross and microscopic evaluation, pH, and temperature were used to assess physical compatibility. Mass spectrometry was used to evaluate precipitate. High‐performance liquid chromatography was used to quantitate drug concentration, indicating strength. Initial separation of ingredients indicating lack of homogenous mixing, immediate precipitate formation, and an exothermic reaction deterred drug strength measurement in solutions containing an antifungal. Results: On D10, in solutions containing tris‐EDTA, average enrofloxacin concentration decreased 25.4% with 100 mg/mL enrofloxacin, 29.3% with 100 mg/mL enrofloxacin and dexamethasone, 45.6% with 22.7 mg/mL enrofloxacin, and 49.8% with 22.7 mg/mL enrofloxacin and dexamethasone. Precipitate formed in all solutions containing tris‐EDTA and filtration of the precipitate did not impact the measured enrofloxacin concentration. Compatibility and stability of enrofloxacin were verified in all solutions containing sterile water. Conclusions and Clinical Relevance: Clinical use of solutions containing enrofloxacin combined with tris‐EDTA or an antifungal is injudicious owing to incompatibility and instability.